According to filings with the U.S. Securities and Exchange Commission, Inocras has raised $31 Million in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, Shinhan Securities, NDS Corporation, Aimed Bio Inc., DSC Investment, Dunamu & Partners, InterVest

About Inocras
Inocras is a bioinformatics-led company focused on whole genome data and proprietary analytics to deliver curated insights for precision health. Its website describes the company as unlocking the power of the whole genome at scale by breaking through technology and cost barriers so genomic insights can be more accessible. Inocras emphasizes whole genome insights and actionable answers, positioning itself around transforming DNA data into useful information for clinical decision-making. The company also highlights its provider-facing test ordering process and patient services, indicating that it offers genomics-based testing and reporting for healthcare use. A notable achievement mentioned on the site is its $31 million oversubscribed Series B-3 financing, which it says will help accelerate U.S. commercial expansion.

To learn more, visit https://inocras.com/
Linkedin: https://www.linkedin.com/company/inocras-inc

Contact:
Jehee Suh, Chief Executive Officer
https://www.linkedin.com/in/jehee-suh-18ba996

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.